Milne RW - Search Results

1

Targeting CDK9: a promising therapeutic opportunity in prostate cancer.

Rahaman MH, Kumarasiri M, Mekonnen LB, Yu M, Diab S, Albrecht H, Milne RW, Wang S. Rahaman MH, et al. Among authors: milne rw. Endocr Relat Cancer. 2016 Dec;23(12):T211-T226. doi: 10.1530/ERC-16-0299. Epub 2016 Aug 31. Endocr Relat Cancer. 2016. PMID: 27582311 Review.

2

Targeting CDK9 for treatment of colorectal cancer.

Rahaman MH, Lam F, Zhong L, Teo T, Adams J, Yu M, Milne RW, Pepper C, Lokman NA, Ricciardelli C, Oehler MK, Wang S. Rahaman MH, et al. Among authors: milne rw. Mol Oncol. 2019 Oct;13(10):2178-2193. doi: 10.1002/1878-0261.12559. Epub 2019 Aug 21. Mol Oncol. 2019. PMID: 31398271 Free PMC article.

3

MAP kinase-interacting kinases--emerging targets against cancer.

Diab S, Kumarasiri M, Yu M, Teo T, Proud C, Milne R, Wang S. Diab S, et al. Chem Biol. 2014 Apr 24;21(4):441-452. doi: 10.1016/j.chembiol.2014.01.011. Epub 2014 Mar 6. Chem Biol. 2014. PMID: 24613018 Review.

4

CDK5 in oncology: recent advances and future prospects.

Lenjisa JL, Tadesse S, Khair NZ, Kumarasiri M, Yu M, Albrecht H, Milne R, Wang S. Lenjisa JL, et al. Future Med Chem. 2017 Oct;9(16):1939-1962. doi: 10.4155/fmc-2017-0097. Epub 2017 Oct 27. Future Med Chem. 2017. PMID: 29076761 Review.

5

CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Rahaman MH, Yu Y, Zhong L, Adams J, Lam F, Li P, Noll B, Milne R, Peng J, Wang S. Rahaman MH, et al. Invest New Drugs. 2019 Aug;37(4):625-635. doi: 10.1007/s10637-018-0661-2. Epub 2018 Sep 8. Invest New Drugs. 2019. PMID: 30194564

6

Unveiling new chemical scaffolds as Mnk inhibitors.

Diab S, Li P, Basnet SK, Lu J, Yu M, Albrecht H, Milne RW, Wang S. Diab S, et al. Among authors: milne rw. Future Med Chem. 2016;8(3):271-85. doi: 10.4155/fmc.15.190. Epub 2016 Feb 24. Future Med Chem. 2016. PMID: 26910782

7

Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia.

Diab S, Abdelaziz AM, Li P, Teo T, Basnet SKC, Noll B, Rahaman MH, Lu J, Hou J, Yu M, Le BT, Albrecht H, Milne RW, Wang S. Diab S, et al. Among authors: milne rw. Eur J Med Chem. 2017 Oct 20;139:762-772. doi: 10.1016/j.ejmech.2017.08.006. Epub 2017 Aug 3. Eur J Med Chem. 2017. PMID: 28863357

8

Discovery of N-Phenyl-4-(1H-pyrrol-3-yl)pyrimidin-2-amine Derivatives as Potent Mnk2 Inhibitors: Design, Synthesis, SAR Analysis, and Evaluation of in vitro Anti-leukaemic Activity.

Abdelaziz AM, Diab S, Islam S, Basnet SKC, Noll B, Li P, Mekonnen LB, Lu J, Albrecht H, Milne RW, Gerber C, Yu M, Wang S. Abdelaziz AM, et al. Among authors: milne rw. Med Chem. 2019;15(6):602-623. doi: 10.2174/1573406415666181219111511. Med Chem. 2019. PMID: 30569866

9

Discovery of 5-(2-(phenylamino)pyrimidin-4-yl)thiazol-2(3H)-one derivatives as potent Mnk2 inhibitors: synthesis, SAR analysis and biological evaluation.

Diab S, Teo T, Kumarasiri M, Li P, Yu M, Lam F, Basnet SK, Sykes MJ, Albrecht H, Milne R, Wang S. Diab S, et al. ChemMedChem. 2014 May;9(5):962-72. doi: 10.1002/cmdc.201300552. Epub 2014 Feb 12. ChemMedChem. 2014. PMID: 24677692

10

Targeting Pim kinases for cancer treatment: opportunities and challenges.

Le BT, Kumarasiri M, Adams JR, Yu M, Milne R, Sykes MJ, Wang S. Le BT, et al. Future Med Chem. 2015;7(1):35-53. doi: 10.4155/fmc.14.145. Future Med Chem. 2015. PMID: 25582332 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

184 results

Search Page